FIELD: medicine, endocrinology, pharmacy.
SUBSTANCE: invention proposes an agent eliciting antidiabetic activity. Agent represents nonglycosylated recombinant human granulocyte colony-stimulating factor. It differs from native preparation by absence of glycosyl group and the presence of additional methionine residue by its N-end. Effect of agent is associated with mobilization and migration of bone marrow mesenchymal stem cells, homing into pancreas. This results to reparation of insulin-producing activity of organ and normalization of the peripheral blood glucose level after monotherapy with recombinant human granulocyte colony-stimulating factor.
EFFECT: valuable medicinal property of agent.
3 tbl, 2 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
DRUG POSSESSING REGENERATIVE ACTIVITY | 2011 |
|
RU2480236C1 |
TISSUE REGENERATION STIMULATING AGENT | 2013 |
|
RU2599289C2 |
METHOD FOR TREATING EXPERIMENTAL CHRONIC TOXIC HEPATITIS | 2005 |
|
RU2295971C1 |
METHOD FOR TREATMENT OF PATIENTS WITH DIABETES MELLITUS | 2003 |
|
RU2240134C1 |
MEANS FOR TREATING DIABETES | 2000 |
|
RU2165767C1 |
NOVEL CHELATE COMPOUND OF OXOVANADIUM (IV) WITH ISONICOTINIC ACID HYDRAZIDE SHOWING ANTIDIABETIC ACTION AND ELICITING ANTIMYCOBACTERIAL ACTIVITY | 1999 |
|
RU2190618C2 |
AGENT HAVING HYPOGLYCEMIC AND ANTI-INFLAMMATORY ACTIVITY | 2012 |
|
RU2506091C1 |
METHOD FOR CARRYING OUT EXPERIMENTAL MYOCARDIAL INFARCTION THERAPY | 2005 |
|
RU2288738C2 |
MEDICINAL PRODUCT FOR DIABETES TREATMENT | 2006 |
|
RU2329813C2 |
METHOD OF GRANULOCYTOPOIESIS DEPRESSION CORRECTION IN CYTOSTATIC ACTION | 2008 |
|
RU2366422C1 |
Authors
Dates
2007-12-27—Published
2006-05-22—Filed